Med Ad News’ Post

🌟 Exciting News! 🌟 Our very own Elizabeth has shared some invaluable insights on payer dynamics in the rare disease space in Med Ad News. Her expertise and perspective shed light on the unique challenges and opportunities within this critical area of healthcare. #MarketAccess #MosaicGroup #PayerDynamics #RareDisease #ExpertInsight

𝘼𝙘𝙘𝙤𝙧𝙙𝙞𝙣𝙜 𝙩𝙤 Polaris Market Research & Consulting , 𝙩𝙝𝙚 𝙜𝙡𝙤𝙗𝙖𝙡 𝙩𝙧𝙖𝙣𝙨𝙙𝙚𝙧𝙢𝙖𝙡 𝙙𝙧𝙪𝙜 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙨𝙮𝙨𝙩𝙚𝙢𝙨 𝙢𝙖𝙧𝙠𝙚𝙩 𝙨𝙞𝙯𝙚 𝙖𝙣𝙩𝙞𝙘𝙞𝙥𝙖𝙩𝙚𝙙 𝙩𝙤 𝙜𝙧𝙤𝙬 𝙛𝙧𝙤𝙢 𝙐𝙎𝘿 𝟐𝟖.𝟓𝟓 𝙗𝙞𝙡𝙡𝙞𝙤𝙣 𝙞𝙣 𝟐𝟎𝟐𝟒 𝙩𝙤 𝙐𝙎𝘿 𝟒𝟎.𝟎𝟏 𝙗𝙞𝙡𝙡𝙞𝙤𝙣 𝙗𝙮 𝟐𝟎𝟑𝟐, 𝙚𝙭𝙝𝙞𝙗𝙞𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝘾𝘼𝙂𝙍 𝙤𝙛 𝟒.𝟑% 𝙙𝙪𝙧𝙞𝙣𝙜 𝙩𝙝𝙚 𝙛𝙤𝙧𝙚𝙘𝙖𝙨𝙩 𝙥𝙚𝙧𝙞𝙤𝙙. 𝙈𝙤𝙧𝙚 𝙍𝙚𝙥𝙤𝙧𝙩 𝘿𝙚𝙩𝙖𝙞𝙡𝙨: https://lnkd.in/duERU7Rp Rising healthcare spending and heightened awareness of alternative drug delivery methods are propelling the transdermal drug delivery systems market. With increasing global healthcare expenditures, there's a growing need for cost-effective treatments offering improved patient outcomes. #TransdermalDrugDeliverySystemsMarket #TransdermalDrugDeliverySystemsIndustry #TransdermalDrugDeliverySystems #marketresearch #marketresearchreports #polarismarketresearch

Dr. Milind Antani, Lead- Pharma, Healthcare, Medical Device and Digital Healthcare practice, Nishith Desai Associates, shed light on the dynamic changes in diseases, illnesses, and patient profiles driven by various factors in this new age. To tackle these shifts, he emphasized the critical role of the pharmaceutical industry in pioneering new solutions to address and eliminate mutating diseases. #ValueOfInnovation #BharatKeLiye

Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies🖋️Mike Christel Bill Lobb, Vice President, Strategic Initiatives, Enterprise Medical Solutions, and Jack Mycka Vice President, Enterprise Medical Solutions and Emerging Biotech; both of Indegene #industrytrends #pharmaceuticalindustry #lifesciences

Product launches & IRA impact are perhaps 2 of the most pressing topics discussed in upper echelons of the LifeSciences commercialization leadership. Last week’s senator hearing tells us how complex this topic is. Just a glimpse of the challenges ahead in 2024 in this area: “First, they’re going to have to determine whether their price adjustments have triggered an inflation penalty and pay that money back,” notes Bill Lobb on initial adaptive measures for manufacturers. “Second, there is the price they’re going to be negotiating—and the way Medicare Part D drugs work now is you negotiate as a manufacturer with the [prescription drug plans] to solve for the formularies. So we’re talking about negotiations for formularies in 2025, for example, that are independent of the centralized negotiations that are within the IRA structure.” #BayArea #LifeSciences #NewJersey #johnsonandjohnson #bms #merck #Pharma - Talk to Market Access and pricing specialists at #Indegene

Hydery and Reddy (2024) present a concise primer on drug formularies. A formulary is an updated list of medications, products, and technologies, aiming to facilitate therapy access while promoting resource utilization. Formulary structures include closed, open, tiered, and value-based types. Payers consider trends like biosimilars, digital therapeutics, and health equity in formulary development. via Healthcare Economist https://ift.tt/6UeAX5q March 09, 2024 at 12:25PM #healthpolicy, #healthsystems, #policy

In recent years we have seen a significant paradigm shift occurring in the realm of pain management. With a growing frustration towards traditional healthcare systems and a decreasing trust in pharmaceutical interventions, patients are seeking non-invasive, non-drug solutions to their chronic pain concerns. Sarah Campbell, Marketing Director at Venn Healthcare Ltd shares her thoughts on "Revolutionizing Pain Management: Bridging the Gap with Regenerative Technologies", check out her latest article recently published in Medhealth Review :https://lnkd.in/ecbAEQsb

#ICYMI: The June 2024 issue of Drug Topics spotlights important #conversations from #AXS24, the Asembia Specialty Pharmacy Summit. Experts forecast #pharmacy trends in 2025 and beyond, talk about the potential impact of the upcoming presidential #election, explore health system #sustainability, and more. https://lnkd.in/eZuk5nZj

During the Clinical Trials Forum 2024 yesterday, our managing director Sabrina Suetens discussed various matters with Caroline Ven, CEO of pharma.be. Clinical trials are a crucial engine of innovation in healthcare. 🤝 In this context, it is important for the #pharma and #medtech sector to collaborate closely. Together, we can target therapies even more precisely, monitor the effects of treatments even more effectively, etc. 💗 In other words, by working together, we can create even greater impact for patients. #ClinicalTrialsForum #clinicaltrials #medicaltechnology #healthinnovation FAGG - Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten

How did people end up consuming a carcinogen for years !!!! In 2019, I vividly recall being part of an industry that experienced a significant wake-up call. Ranitidine, a trusted medication, more commonly known as Zantac, was suddenly in the spotlight for all the wrong reasons. The culprit? The unsettling presence of a potential carcinogen, N-nitrosodimethylamine (NDMA). This recall hit close to home for me as it was a stark reminder of why I chose a career in pharmaceuticals in the first place – to improve the lives of patients and ensure their safety above all else. The recall underscored that the pharmaceutical industry is not immune to challenges, and it's our responsibility to address them head-on. The discussions and evaluations that followed within our industry were a testament to our commitment to patient well-being. It's in these moments of crisis that we must come together, reevaluate our practices, and prioritize transparency, accountability, and continuous innovation. As we look back on the Ranitidine recall, let's not forget the lessons learned. We're in an industry where lives are on the line, and it's our duty to ensure that every medication meets the highest safety standards. Here's to a future where our unwavering commitment to patient safety drives us to even greater heights in delivering healthcare solutions that transform lives. #PharmaceuticalIndustry #PatientSafety #DrugRecall #Healthcare #PharmaSafety #NDMA #ZantacRecall #PersonalReflection